Targeting QPCTL: An Emerging Therapeutic Opportunity
Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 929-943
DOI: 10.1021/acs.jmedchem.4c02247 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.01.2025. Verfasst von Lei Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Hauptthemen laut MEDLINE: Aminoacyltransferases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glutaminyl cyclases, including glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), primarily catalyze the cyclization of N-terminal glutamine or glutamate to pyroglutamate (pGlu). QPCTL, in particular, modifies the N-terminus of CD47, thereby regulating its interaction with signal-regulatory protein alpha (SIRPα) and modulating phagocytosis of tumor cells by immune cells. Additionally, QPCTL cyclizes the N-termini of CCL2, CCL7, and CX3CL1, influencing the tumor microenvironment and inflammatory responses in cancer and other disorders. Consequently, QPCTL is considered a valuable therapeutic target for several human diseases. However, the development of QPCTL inhibitors remains in its early stages. This perspective summarizes the structural features, catalytic mechanisms, and biological functions of QPCTL, along with its recent advances in small-molecule inhibitors. It provides valuable insights into the development of novel QPCTL inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
ORCID-Profile: Shilin Xu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Yu, L., Sun, Y., Xie, L., Tan, X., Wang, P., & Xu, S. (2025). Targeting QPCTL: An Emerging Therapeutic Opportunity. Journal of Medicinal Chemistry, 68(2), 929-943. https://doi.org/10.1021/acs.jmedchem.4c02247
Vancouver
Yu L, Sun Y, Xie L, Tan X, Wang P, Xu S. Targeting QPCTL: An Emerging Therapeutic Opportunity. Journal of Medicinal Chemistry. 2025;68(2):929-943. doi:10.1021/acs.jmedchem.4c02247
BibTeX
@article{Yu2025,
author = {Yu, Lei and Sun, Yaoliang and Xie, Longyan and Tan, Xiao and Wang, Ping and Xu, Shilin},
title = {Targeting QPCTL: An Emerging Therapeutic Opportunity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {2},
pages = {929--943},
doi = {10.1021/acs.jmedchem.4c02247}
}
EUVIMED